Lifecore Biomedical
LFCR
98 hedge funds and large institutions have $265M invested in Lifecore Biomedical in 2014 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 32 increasing their positions, 38 reducing their positions, and 20 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $296M → $265M (-$31.3M)
12% less funds holding
Funds holding: 111 → 98 (-13)
16% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 38
55% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 20
99% less call options, than puts
Call options by funds: $2K | Put options by funds: $144K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$5.17M |
| 2 |
AI
Ariel Investments
Chicago,
Illinois
|
+$3.83M |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$2.83M |
| 4 |
BCM
Buckhead Capital Management
Atlanta,
Georgia
|
+$1.97M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MOACM
Mutual of America Capital Management
New York
|
-$4.16M |
| 2 |
MCM
McKinley Capital Management
Anchorage,
Alaska
|
-$3.88M |
| 3 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
-$3.16M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.65M |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$2.17M |
LFCR Hedge Fund Activity: Q1 2014 in Review
98 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2014, worth a combined $265M — down 11% from $296M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LFCR and 9 opened new positions — a net loss of 11 holders — while 38 trimmed existing stakes and 32 added.
The largest buyer was Boston Partners, adding an estimated $5.17M. The largest seller was Mutual of America Capital Management, exiting entirely with an estimated $4.16M sold.
- 98 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2014, down from 111 in Q4 2013.
- Funds reported $265M of Lifecore Biomedical stock for Q1 2014, down 11% quarter-over-quarter.
- 9 funds opened new Lifecore Biomedical positions in Q1 2014 and 20 closed out, a net change of -11 holders.
- The largest Lifecore Biomedical buyer in Q1 2014 was Boston Partners, an estimated $5.17M added.
- The largest Lifecore Biomedical seller in Q1 2014 was Mutual of America Capital Management, an estimated $4.16M sold.
Based on aggregated 13F filings for Q1 2014.